In a world-first, Australian researchers and clinicians have shown that precision medicine – where treatment is tailored to an individual child’s cancer – leads to significantly improved outcomes in children with high risk cancer.

In a study published this week in the leading international journal Nature Medicine, the researchers found that precision medicine (also called personalised medicine) was shown to be superior to standard or non-guided therapy, both in terms of clinical response and survival.

A staggering 55% of children who received their personalised treatment achieved complete or partial remission, or had their disease stabilised for at least 6 months.

Given that that these children had highly aggressive cancers which, in many cases, had already failed to respond to standard therapy, these are remarkable results.

These children had been observed for an average of 3 years after receiving their personalised treatment.

Treatment recommendations were given to their oncologists after detailed genetic analysis of the driver genes in the tumour.

This strategy matched the drug better to each child’s cancer driver genes, often suggesting drugs that are not normally used to treat that cancer type.

The results show, for the first time, that this had led to an improvement in progression-free survival.

“These are very exciting results which we believe have important implications for the treatment of children with cancer,” said Professor David Ziegler, Chair of Clinical Trials for the Zero Childhood Cancer Program and senior author on the paper.

“We’ve already shown that precision medicine can help identify new treatment options for many high-risk patients. Now we’ve shown that it not only can shrink their tumours, but also lead to a significant improvement in long term survival for those patients.”

Over a minimum follow-up period of 18 months, the study included 384 children with high-risk cancers (with a very low chance of cure) enrolled on the Zero Childhood Cancer Program (ZERO), Australia’s national precision medicine program for children with cancer.

ZERO is jointly led by Children’s Cancer Institute and Kids Cancer Centre at Sydney Children’s Hospital, Randwick and involves 9 child cancer treatment centres in the country.

This study involved more than 100 scientists and clinicians working together across all these 9 child cancer centres.

To determine the impact on survival, the researchers measured ‘progression-free survival’, the length of time that a patient lives without their cancer getting any worse.

The results showed that children who received a ZERO-recommended treatment did significantly better than those who did not.

In fact, their 2-year progression-free survival was more than double that of children who received standard therapy (26% vs 12%), and five times higher than that of children who received an unguided treatment (a novel agent not chosen on the basis of molecular findings).

Importantly, the study found that children who received their recommended therapy early on in their treatment pathway did significantly better than those who received it after their disease had progressed, suggesting that the sooner a personalised treatment strategy can be implemented, the better the chance of preventing relapse and death.

Associate Professor Loretta Lau, a paediatric molecular oncologist at Kids Cancer Centre, researcher at Children’s Cancer Institute and first author on the paper, and Professor Glenn Marshall AM, Clinical Lead of ZERO and co-senior author on the paper, said the world-first study shows that precision medicine has the potential to change the model of care for children with cancer.

“Our study provides important new evidence that response to precision-guided therapy translates into improved survival,” said A/Prof Lau and Prof Marshall.

“This work provides some hope to families where none previously existed in a new model of treatment for high-risk childhood cancer which is changing national and international clinical practice.”

Prof Ziegler, who is both a paediatric oncologist at the Kids Cancer Centre and a research leader at Children’s Cancer Institute, said, “We’ve shown that matching a therapy to a patient through molecular analysis of their cancer, and implementing that targeted therapy early on, are key to achieving the best possible results.” 

Supported by the Australian Government and Minderoo Foundation and sponsored by the Australian and New Zealand Children’s Haematology and Oncology Group (ANZCHOG), ZERO’s first national precision medicine trial began in 2017, focusing on identifying new treatment options for children with high-risk cancers.

The success of this clinical trial led to joint funding of $67 million from the Australian Government ($55.8 million through the Department of Health’s Medical Research Future Fund) and Minderoo Foundation ($12.2 million) being awarded in 2020 to expand the program to be available to all 1200 Australians aged 0-18 years who are diagnosed with cancer—which was achieved in 2023.

It is the first time that precision medicine has been made available to every child diagnosed with cancer, not just in Australia, but in any country in the world.

Source: Tania Ewing and Associates